Keyphrases
Chemotherapy
100%
EGFR mutation
100%
Non-small Cell Lung Cancer Patients
100%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
100%
Lung Cancer Outcomes
100%
Epidermal Growth Factor Receptor
55%
Non-small Cell Lung Cancer (NSCLC)
44%
Platinum-based Chemotherapy
44%
Median Progression-free Survival
44%
Adenocarcinoma
22%
Objective Response Rate
22%
Uncommon mutation
22%
Independent Prognostic Factor
22%
G719X
22%
L861Q
22%
Tyrosine Kinase Inhibitor Treatment
22%
Clinical Activity
11%
Tyrosine Kinase Inhibitor
11%
Multivariate Analysis
11%
First-line Therapy
11%
Treatment Outcome
11%
Clinical Characteristics
11%
Patient Survival
11%
Clinical Treatment
11%
Treatment Group
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Epidermal Growth Factor Receptor
100%
Progression Free Survival
40%
Adenocarcinoma
20%
Protein Tyrosine Kinase Inhibitor
10%
Treatment Group
10%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Progression Free Survival
40%
Adenocarcinoma
20%
Predictive Factor
20%
Tyrosine-Kinase Inhibitor
10%
Treatment Group
10%
Multivariate Analysis
10%
Treatment Outcome
10%